1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Biologics Evaluation and Research (CBER)
  5. Biologics Electronic Reading Room (eFOIA)
  1. Center for Biologics Evaluation and Research (CBER)

Biologics Electronic Reading Room (eFOIA)

 
Bookshelf

The Center for Biologics Evaluation and Research Freedom of Information Act (FOIA) Electronic Reading Room contains copies of CBER records (or links to other locations of CBER records) that we are making publicly available: (1) because the records are required to be published on the web by the Food, Drug and Cosmetic Act, (2) because they are “frequently requested” records under the FOIA (5 U.S.C. § 552(a)(2)(D)) or (3) proactively at our discretion. We will continue to add records to reflect public interest. 


 
Compass

Information of Interest

Pfizer-BioNTech Comirnaty COVID-19 Vaccine Related Records | Powered by BOX

*Due to the volume, complexity and file size of this collection, the majority of the records are not Section 508 compliant. If you need assistance with any of these files, please call 240-402-7800. In addition, this collection of records contains .xml, .mp3, .txt, .xsl, and .xpt files which may require additional software in order to access.

Note: The majority of the files have a prefix added to the file name that is indicative of the standard submission format used in the Electronic Common Technical Document (eCTD) database. For additional information regarding the eCTD, please see the link below: https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd

Additional Comirnaty Related Records


 
Person holding a magnifying glass over a piece of paper

Frequently Requested Records*

* - The Freedom of Information Act, 5 U.S.C. § 552(a)(2)(D) “copies of all records, regardless of form or format - (i) that have been released to any person under paragraph (3); and (ii)(I) that because of the nature of their subject matter, the agency determines have become or are likely to become the subject of subsequent requests for substantially the same records; or (II) that have been requested 3 or more times;”

 
Date PostedRecords Description
10/29/2025FDA Form 483 Samsung Biologics Co, Yeonsu, Korea May 2025
09/30/2025FDA Form 438 Serum Institute of India, Pune, India, June 2024
09/30/2025FDA Form 438 Grifols, Barcelona, Spain, July 2024
09/25/2025FDA Form 483 Takeda Manufacturing, Singapore, Nov 2018
09/25/2025FDA Form 483 Krystal Biotech Inc., Pittsburgh, PA Jan 2025
09/24/2025FDA Form 483 JMS Healthcare, Batangas, Philippines, May 2023
09/24/2025FDA Form 483 IDT Biologika GmbH, Dessau-Rosslau, Germany Aug 2023
09/24/2025FDA Form 483 GSK, Nord, France, March 2024
09/24/2025FDA Form 483 GSK Vaccines GmbH, Marburg, Germany Feb 2024
09/23/2025FDA Form 483 Capricor Inc., San Diego, CA May 2025
09/23/2025FDA Form 483 ADMA Biologics Inc., Boca Raton, FL Dec 2024
09/05/2025FDA Form 483 ARUP Laboratories, Inc, Sandy, UT Oct 2024
09/05/2025FDA Form 483 Janssen, Raritan, NJ Oct 2024
09/05/2025FDA Form 483 Patheon Italia SpA Monza, Italy Sept 2023
09/05/2025FDA Form 483 SeaStar Medical Inc., Denver, CO Feb 2025
09/02/2025FDA Form 483 Eone Laboratories, Incheon, Korea, Aug 2023
09/02/2025FDA Form 483 Pfizer, Sanford, NC Nov 2023
09/02/2025FDA Form 483 LFB Manufacturing, Gard, France, Sept 2022
08/25/2025FDA Form 483 Valneva, Livingston, Scotland Sept 2022
03/28/2025FDA Form 483 Charles River Laboratories Memphis TN October 2024
03/28/2025FDA EIR Catalent Maryland March 2023
11/05/2024FDA Form 483 Roslin Cell Therapies Ltd., Edinburgh, UK Aug 2023
10/17/2024FDA Form 483 Berkshire Sterile Manufacturing,  Lee, MA  Jan 2023
10/17/2024FDA Form 483 Humacyte Global Inc, Durham, NC, April 2024
10/17/2024FDA Form 483 Lonza Netherlands BV, Geleen, Netherlands, July 2024
10/17/2024FDA Form 483 Resilience US, Inc. Durham, NC, Feb 2024
10/17/2024FDA Form 483 WuXi Advanced Therapies, Philadelphia, PA Aug-Sep 2023
07/09/2024FDA EIR Aldevron, LLC Fargo, ND November 2021
06/18/2024FDA Form 483 FUJINOMIYA FACTORY OF TERUMO CORP Fujinomiya, Japan May 2023
04/25/2024FDA Form 483 Fenwal International Inc. Bajos De Haina, Dominican Republic April 2023
04/25/2024FDA Form 483 Novo Nordisk Kalundborg, Denmark April-May 2023
04/25/2024FDA Form 483 Krystal Biotech Inc, Pittsburgh, PA November 11-16, 2022
04/16/2024FDA Form 483 BioMarin Pharmaceuticals, Inc., Novato, CA  December 2022
04/16/2024FDA Form 483 Bristol Myers Squibb, Devens, MA May 2023
04/16/2024FDA Form 483 Samsung Biologics Co. Yeonsu-gu, Republic of Korea Feb. 2023
04/01/2024BLA 125062-674 June 28, 2021 Pharmacovigilance Plan Review Memo
04/01/2024BLA 125062-674 June 22, 2021 Memo Committee Memo Statistical Review
04/01/2024BLA 125062-674 June 22,2021 Memo Other Final Draft Labeling
04/01/2024BLA 125062-674 June 23, 2021 Memo Committee Memo CMC
04/01/2024BLA 125062-674 June 29, 2021 Memo Committee Memo Preclinical Pharm-Tox Review
04/01/2024BLA 125062-674 July 14, 2021 Memo Committee Memo BIMO Review Memo
04/01/2024BLA 125062-674 July 15, 2021 Memo Committee Memo Clinical
03/20/2024August 19, 2020 Lucina BioSciences LLC Response Letter (TRG)
03/04/2024CBER Laboratory Quality System Laboratory Procedure Test-Cal Method (TM) Document ID 000333
01/18/2024FDA Form 483 Millipore UK Ltd, Livingston, UK February 2020
11/20/2023FDA Form 483 Christine H Lee (Royal Jubilee Hospital) Victoria, British Columbia, Canada June 2022
08/11/2023FDA Form 483 Catalent Harmans, Maryland March 2023
07/14/2023Marion Gruber August 13, 2021 Email
07/14/2023Phil Krause August 30, 2021 Email
07/14/2023FDA Form 483 Paragon Gene Therapy - Catalent Harmans, Maryland June 2020
06/07/2023IHCTOA Letters
04/11/2023FDA Form 483 Dendreon Corporation Morris Plains, NJ February 2007
04/11/2023FDA Form 483 Dendreon Corporation Morris Plains, NJ January 2010
08/15/2022Bavarian Nordic A/S Response Letter - August 12, 2022

 
Lightbulbs with the filaments spelled out to the words "help", "support", "assistance", "guidance"

Additional Information

Back to Top